Vivimed gets DGHI nod to manufacture, market favipiravir tablet in India
The drug will be marketed under Vivimed’s brand name ‘Favulous’ across India
Vivimed Labs announced the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg under Vivimed’s own brand name ‘Favulous’ across India. It is used for the treatment of mild to moderate cases of COVID-19. Favipiravir is an oral anti-viral treatment approved in various countries for the potential treatment of patients with mild to moderate COVID-19 disease.
Commenting on the launch, Ramesh Krishnamurthy, CEO of Vivimed Labs said, “With a huge spike in COVID-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching “Favulous” at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden.”